Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Laura Khandagle

Internal Medicine Silver Spring, MD Medical Doctor

NPI 1235112905 CMS profile 100798

831 University Blvd E, Suite 25, Silver Spring, MD 20903

Open in the dashboard

General payments

$4,343

244 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Laura Khandagle of Silver Spring, MD is reported in the CMS Open Payments database as having received $4,343 across 244 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,092 50
2024 General $1,347 62
2023 General $365 19
2022 General $51 4
2021 General $13 1
2020 General $294 18
2019 General $1,181 90

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Laura Khandagle
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Laura Khandagle were reported at $1,092. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Laura Khandagle Internal Medicine median Middle half National median
2019 $1,181 $159 $48–$570 $163
2020 $294 $119 $33–$402 $114
2021 $13 $135 $37–$521 $132
2022 $51 $141 $42–$496 $149
2023 $365 $149 $45–$519 $160
2024 $1,347 $154 $47–$537 $164
2025 $1,092 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $709 36 payments
  2. Lilly USA, LLC $598 29 payments
  3. AstraZeneca Pharmaceuticals LP $455 25 payments
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $265 11 payments
  5. Amgen Inc. $261 14 payments
  6. AbbVie, Inc. $225 11 payments
  7. Pfizer Inc. $219 13 payments
  8. Astellas Pharma US Inc $172 9 payments
  9. Merck Sharp & Dohme Corporation $153 11 payments
  10. Horizon Therapeutics plc $117 24 payments
  11. Other $1,169 61 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,310 241 payments
  2. Education $34 3 payments
Products named General payments · program years 2019–2025
  1. Ozempic $501 25 payments
  2. MOUNJARO $392 17 payments
  3. RYBELSUS $347 17 payments
  4. JARDIANCE Diabetes $198 8 payments
  5. ZEPBOUND $179 8 payments
  6. NURTEC ODT $148 8 payments
  7. MYRBETRIQ $137 8 payments
  8. Wegovy $136 5 payments
  9. AIRSUPRA $130 6 payments
  10. JARDIANCE Diabetes $117 7 payments
  11. Other $3,953 244 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 122 drugs

Part D claims

5,449

Median for Internal Medicine: 777

Drug cost

$742,533

Median for Internal Medicine: $73,373

Branded share of claims

22.2%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mounjaro Tirzepatide Brand 94 $182,475
Ozempic Semaglutide Brand 84 $173,676
Jardiance Empagliflozin Brand 61 $79,066
Rybelsus Semaglutide Brand 17 $39,198
Eliquis Apixaban Brand 31 $38,582
Januvia Sitagliptin Phosphate Brand 25 $29,598
Tresiba Flextouch U-200 Insulin Degludec Brand 23 $20,703
Entresto Sacubitril/Valsartan Brand 17 $18,131
Tradjenta Linagliptin Brand 16 $14,141
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 14 $9,243

The 10 drugs with the highest cost, of 122 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 30 billing codes

Paid by Medicare

$150,980

Of which drugs: $4,046

Medicare patients

435

Average age 75

Services billed

2,071

376 women, 59 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 47%
Diabetes 29%
Osteoporosis 27%
Chronic kidney disease 23%
Ischemic heart disease 21%
Cancer 15%
Depression 13%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Influenza vaccine, trivalent derived from cell cultures 90661 Office 76 76 $2,744
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 13 20 $19

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 33 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
MOUNJARO
  • Lilly USA, LLC $186
$186 94 —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $123
  • Lilly USA, LLC $33
$155 61 —
REXULTI
  • Lundbeck LLC $107
  • Otsuka America Pharmaceutical, Inc. $26
$133 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $109
$109 — —
RYBELSUS
  • Novo Nordisk Inc $56
$56 17 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 33 with Patron

Records

244 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record